Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR-Reference-Cited by-同舟云学术

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR

Published:2018-05-01 Issue:5 Volume:154 Page:581
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Mason Kayleigh J.¹,Barker Jonathan N. W. N.²,Smith Catherine H.²,Hampton Philip J.³,Lunt Mark¹,McElhone Kathleen¹,Warren Richard B.¹⁴,Yiu Zenas Z. N.⁴⁵,Griffiths Christopher E. M.¹⁴,Burden A. David⁶,

Affiliation:

1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom

2. St John's Institute of Dermatology, Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom

3. Newcastle Dermatology, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom

4. Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom

5. Centre for Pharmacoepidemiology and Drug Safety, The University of Manchester, Manchester, United Kingdom

6. Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Dermatology

Reference21 articles.

1. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.;Garcia-Doval;Arch Dermatol,2012

2. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.;Schmitt;Br J Dermatol,2008

3. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response.;Eichler;Nat Rev Drug Discov,2011

4. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives.;Burden;Br J Dermatol,2012

5. Etanercept as monotherapy in patients with psoriasis.;Leonardi;N Engl J Med,2003

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO);Dermatology and Therapy;2023-12-19

2. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT);Journal of the European Academy of Dermatology and Venereology;2023-12-12

3. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study;Acta Dermato-Venereologica;2023-11-21

4. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group;Journal of the European Academy of Dermatology and Venereology;2023-09

5. Durability and long-term outcomes of biologic therapies in psoriasis;Expert Review of Clinical Immunology;2023-08-25